Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update.

Clinical pharmacology and therapeutics - 1 Aug 2026

Moore Claire, Bourque Melissa S, Halman Andreas, Agúndez José A G, Prows Cynthia A, Hikino Keiko, Schwab Matthias, Oxencis Carolyn J, Chauhan Dharmisha, Diekstra Meta H M, Long Susie E, Bell Gillian C, Gaedigk Andrea, Whirl-Carrillo Michelle, Klein Teri E, Caudle Kelly E, Conyers Rachel

Abstract excerpt

5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nausea

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Vomiting

Source

Open in PubMed Open full text

Identifiers

PMID: 41979467
DOI: 10.1002/cpt.70291
PMCID: PMC13339002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update.PMID 41979467Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetronSemantic proximity Read ↗

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis.Semantic proximity Read ↗

The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogeneticsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Semantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.